<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01514929</url>
  </required_header>
  <id_info>
    <org_study_id>ACHN-490-006</org_study_id>
    <nct_id>NCT01514929</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of IV ACHN-490 Injection on the QT/QTc Interval in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo and Positive-Controlled, Crossover Study to Evaluate the Effect of IV ACHN-490 Injection on the QT/QTc Interval in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achaogen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Achaogen, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the study drug, ACHN-490 Injection, affects the
      QT interval in normal volunteers. The hypothesis is that the drug will not cause an increase
      in the QT interval.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>1 day</time_frame>
    <description>In Part 1, the safety and tolerability of a single 20 mg/kg dose of ACHN-490 Injection will be assessed by measuring adverse events, blood pressure and other vital sign measurements, incidence and magnitude of clinically significant changes from baseline in clinical laboratory values (hematology, chemistry, and urinalysis), and physical examination, through 24 hours after study drug administration or resolution of all adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of ACHN-490 Injection on QTcF</measure>
    <time_frame>24 hours</time_frame>
    <description>The primary endpoint for Part 2 of this study is the time-matched change from baseline in QTcF within 24 hours of receiving study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK Parameters</measure>
    <time_frame>24 hours</time_frame>
    <description>The secondary endpoints for Part 1 of this study will include relevant PK parameters such as AUC0-t, AUC0-∞, CLT, Vss, Cmax, Tmax, and t1/2 measured for 24 hours after receiving study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG Parameters</measure>
    <time_frame>24 hours</time_frame>
    <description>Part 2 of the study will measure the effect of ACHN-490 Injection compared to placebo within 24 hours of study drug administration on heart rate, PR interval, QRS interval, QTcB, uncorrected QT interval, RR intervals, change in ST and T-wave morphology, and categorical change in QTc variables.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameters</measure>
    <time_frame>24 hours</time_frame>
    <description>Part 2 of this study will measure multiple PK parameters such as AUC0-t, AUC0-∞, CLT, Vss, Cmax, Tmax, and t1/2 measured for 24 hours after receiving study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between drug concentration and QTc</measure>
    <time_frame>24 hours</time_frame>
    <description>Part 2 of this study will measure the correlation between the QTc change from baseline and plasma concentrations of ACHN-490 Injection within 24 hours of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Up to 44 days</time_frame>
    <description>Part 2 of this study will measure safety and tolerability of ACHN-490 Injection including adverse events, incidence and magnitude of clinically significant changes from baseline in clinical laboratory values (hematology, chemistry, and urinalysis) and physical examination; all for up to 44 days after receiving study drug.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Cardiac Effects in Normal Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Supratherapeutic Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20mg/kg ACHN-490 Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Possible Therapeutic Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg/kg ACHN-490 Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400mg moxifloxacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACHN-490 Injection</intervention_name>
    <description>20mg/kg IV 30 minute infusion given once</description>
    <arm_group_label>Supratherapeutic Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACHN-490 Injection</intervention_name>
    <description>15mg/kg IV 30 minute infusion given once</description>
    <arm_group_label>Possible Therapeutic Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>400mg oral pill given once</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo oral pill given once</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects between 18 and 50 years of age and with a body mass index ≥
             18 to ≤ 33 kg/m2, and weight of ≥ 40 to ≤ 100 kg inclusive.

          2. Subject is in good health as judged by the investigator based on the laboratory
             criteria and no clinically significant findings on the medical history or physical
             examination.

          3. Females of child-bearing potential (defined as less than one year post-menopause) are
             eligible for enrollment if they are not breast feeding, they have a negative serum
             pregnancy test before study entry, and they are using a highly effective method of
             contraception for at least 3 months before study drug administration, during the
             study, and for at least 6 months after study completion.

          4. Subjects who are willing to comply with all study activities and procedures and have
             provided written informed consent prior to any study procedures and have signed and
             dated a Health Insurance Portability and Accountability Act (HIPAA) authorization
             form.

        Exclusion Criteria:

          1. A history of additional risk factors for TdP.

          2. Unstable cardiovascular disease, including recent myocardial infarction or cardiac
             arrhythmia.

          3. Sustained supine systolic blood pressure &gt;150 mmHg, or &lt;110 mmHg in Part 1 or &lt;100mmHg
             in Part 2, or a diastolic blood pressure &gt;95 mmHg at screening or baseline.

          4. A resting pulse rate at rest, taken during screening, of &lt;40 bpm or &gt;100 bpm.

          5. An abnormal screening ECG indicating a second- or third-degree atrioventricular (AV)
             block, or one or more of the following: QRS &gt;110 milliseconds (msec), QTcB &gt;470 msec
             for females or 450 msec for males, PR interval &gt;240 msec, or any rhythm other than
             sinus rhythm, which is interpreted by the Investigator to be clinically significant.

          6. Uncontrolled hypertension, asthma, unstable diabetes (type I or type II), thyroid
             disease, seizures, myasthenia gravis, or any other neuromuscular disorder.

          7. Positive results at screening for hepatitis B virus, hepatitis C virus (HCV), or human
             immunodeficiency virus (HIV) infection.

          8. History of central nervous system disorders, epilepsy or known seizure disorder
             (excluding a history of childhood febrile seizures).

          9. The subject has a history of any cancer, except basal cell or stage 1 squamous cell
             carcinoma of the skin, which has not been in remission for at least 5 years prior to
             the first dose of study drug.

         10. Subjects who have any condition possibly affecting drug absorption.

         11. History of significant hearing loss or a family history of hearing loss, excluding age
             related (≥ age 65) hearing loss. A prior diagnosis of sensorineural hearing loss or
             Ménière's disease.

         12. Clinically significant illness, including viral syndromes within 3 weeks of dosing.

         13. The use of concomitant medications that prolong the QT/QTc interval.

         14. Used prescription medications, over-the-counter (OTC) medications, investigational
             medications/therapy, vitamins, or nicotine-containing products (eg, cigarettes,
             cigars, chewing tobacco, snuff, etc.) within 28 days or 5 half-lives, whichever is
             longer, before dosing of ACHN-490 Injection.

         15. Used aminoglycosides within 6 months prior to IMP administration.

         16. Used herbal preparations including St. John's wort, ginseng, kava kava, ginkgo biloba,
             melatonin, and other nutraceuticals within 28 days prior to IMP administration.

         17. Consumed caffeine- or xanthine-containing products (eg, tea, coffee, chocolate, cola,
             etc.), Seville oranges (sour), grapefruit, grapefruit juice, or fish liver oils within
             72 hours prior to IMP administration.

         18. Current participation in a clinical study of an investigational product.

         19. Consumed more than 28 units of ethanol per week at any time in the 6 months before
             dosing (1 unit of ethanol is equivalent to 8 ounces of beer, 4 ounces of wine, or 1
             ounce of spirits) or history of alcoholism and/or drug/chemical abuse. Also,
             consumption of any amount of ethanol within 72 hours of ACHN-490 Injection dosing.

         20. Donated blood or blood components within 60 days prior to receiving study drug.

         21. Women who are pregnant (or planning to become pregnant within the next 3 months) or
             currently breastfeeding.

         22. Previous participation in this or any other ACHN-490 Injection study.

         23. Known hypersensitivity to aminoglycosides or any component of the ACHN-490 Injection.

         24. Subjects with poor venous access.

         25. Unable to understand verbal or written English or any other language for which a
             certified translation of the informed consent is not available.

         26. Any other medical, psychological, or social condition which, in the opinion of the PI
             or the medical monitor, would prevent the subject from fully participating in the
             study would represent a concern for study compliance or would constitute a safety
             concern to the subject.

         27. An employee of the investigator or study center with direct involvement in the
             proposed study or other studies under the direction of that Investigator or study
             center, as well as a family member of the employee or investigator.

         28. * (Part 1 only) * Acceptable and reproducible spirometry measurements defined as:
             forced expiratory volume in 1 second (FEV1) or forced vital capacity (FVC) &lt; 80% of
             predicted or FEV1/FVC ratio &lt;70% of predicted. See Appendix 7 for definitions of
             acceptability and reproducibility.

         29. * (Part 2 only) * Known hypersensitivity to moxifloxacin or other quinolones.

         30. * (Part 2 only) * Taken antacids, sucralfate, multivitamins, or other products with
             multivalent cations within 8 hours before oral dose in Part 2 or need to take any of
             the above within 4 hours after the dose administration.

         31. * (Part 2 only) * Taken warfarin or Class IA or Class III antiarrhythmics within one
             week prior to study drug administration or expected to need to take any of the above
             during the study period.

         32. * (Part 2 only) * Participation in Part 1 of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Achaogen, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>West Bend</city>
        <state>Wisconsin</state>
        <zip>53095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2011</study_first_submitted>
  <study_first_submitted_qc>January 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2012</study_first_posted>
  <last_update_submitted>May 8, 2012</last_update_submitted>
  <last_update_submitted_qc>May 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thorough QT</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

